2016

High-protein intake during weight loss therapy eliminates the weight-loss-induced improvement in insulin action in obese postmenopausal women

Gordon I. Smith
Washington University School of Medicine in St. Louis

Jun Yoshino
Washington University School of Medicine in St. Louis

Shannon C. Kelly
Washington University School of Medicine in St. Louis

Dominic N. Reeds

Adewole Okunade
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Smith, Gordon I.; Yoshino, Jun; Kelly, Shannon C.; Reeds, Dominic N.; Okunade, Adewole; Patterson, Bruce W.; Klein, Samuel; and Mittendorfer, Bettina, ”High-protein intake during weight loss therapy eliminates the weight-loss-induced improvement in insulin action in obese postmenopausal women.” Cell reports.17,3. 849-861. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5365

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women

Highlights
- A high-protein weight loss (HP-WL) diet preserves lean body mass
- A HP-WL diet prevents the WL-induced improvement in insulin sensitivity
- A HP-WL diet alters WL-induced transcriptional changes in muscle

Authors
Gordon I. Smith, Jun Yoshino, Shannon C. Kelly, ..., Bruce W. Patterson, Samuel Klein, Bettina Mittendorfer

Correspondence
mittendb@wustl.edu

In Brief
Smith et al. found that high-protein intake during weight loss (WL) preserves lean tissue mass but eliminates the WL-induced improvement in muscle insulin action. The authors suggest that this occurs through increasing oxidative stress and modulating WL-induced changes in cell structure and organization.

Accession Numbers
GSE73525
High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women

Gordon I. Smith,1,2 Jun Yoshino,1,2 Shannon C. Kelly,1 Dominic N. Reeds,1 Adewole Okunade,1 Bruce W. Patterson,1 Samuel Klein,1 and Bettina Mittendorfer1,3,*

1Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
2Co-first author
3Lead Contact
*Correspondence: mittendb@wustl.edu
http://dx.doi.org/10.1016/j.celrep.2016.09.047

SUMMARY

High-protein (HP) intake during weight loss (WL) therapy is often recommended because it reduces the loss of lean tissue mass. However, HP intake could have adverse effects on metabolic function, because protein ingestion reduces postprandial insulin sensitivity. In this study, we compared the effects of ~10% WL with a hypocaloric diet containing 0.8 g protein/kg/day and a hypocaloric diet containing 1.2 g protein/kg/day on muscle insulin action in postmenopausal women with obesity. We found that HP intake reduced the WL-induced decline in lean tissue mass by ~45%. However, HP intake also prevented the WL-induced improvements in muscle insulin signaling and insulin-stimulated glucose uptake, as well as the WL-induced adaptations in oxidative stress and cell structural biology pathways. Our data demonstrate that the protein content of a WL diet can have profound effects on metabolic function and underscore the importance of considering dietary macronutrient composition during WL therapy for people with obesity.

INTRODUCTION

Insulin-resistant glucose metabolism is the most common metabolic complication associated with obesity and a key risk factor for developing type 2 diabetes (T2D) and coronary heart disease (Kirk and Klein, 2009). Weight loss (WL) induced by dietary energy restriction is the cornerstone of therapy for people who are obese, because it improves or even normalizes insulin sensitivity and related comorbidities (Klein, 2001). However, diet-induced weight loss also decreases lean tissue (including muscle) mass (Wycherley et al., 2012; Leidy et al., 2015), which could have adverse effects on physical function, particularly in populations who are at increased risk of sarcopenia, such as postmenopausal women (Samson et al., 2000; Phillips et al., 1993). Although increased protein intake during diet-induced weight loss is often recommended, because it helps preserve lean tissue mass (Wycherley et al., 2012; Leidy et al., 2015), data from a series of studies suggest that high protein (HP) intake could have detrimental metabolic effects; acute intravenous amino acid infusion or protein ingestion reduces insulin sensitivity (Smith et al., 2015; Krebs et al., 2002; Robinson et al., 2014), and habitual HP intake is associated with insulin resistance and an increased risk of developing T2D (Linn et al., 1996; Sluijs et al., 2010; Tinker et al., 2011). The effect of increased protein intake per se on weight-loss-induced changes in insulin sensitivity and glucose homeostasis are not known because of the confounding effects of differences in weight loss and food selection and overall diet composition (e.g., consumption of dairy and meat products and saturated and unsaturated fatty acids) between groups in studies that compared HP diets with standard protein diets (Rietman et al., 2014; Wycherley et al., 2012; Schwingshackl and Hoffmann, 2013).

The major purpose of the present study was to conduct a randomized, controlled trial (RCT) to determine whether increasing protein intake as part of a macronutrient-balanced, hypocaloric diet attenuates both the weight loss-induced reduction in lean tissue mass and the beneficial effect of a targeted 8%–10% weight loss on insulin action. Postmenopausal women with obesity were randomized to one of three interventions: (1) a WL group who consumed a hypocaloric diet containing 0.8 g protein/kg body weight per day, (2) a WL-HP diet group who consumed a hypocaloric diet containing 1.2 g protein/kg body weight per day, and (3) a weight-maintenance (WM) control group. Subjects in the WL and WL-HP groups were studied before and after they lost 8%–10% of their initial body weight and were weight stable (<2% change in body weight) for 3–4 weeks, whereas subjects in the WM group were studied after a time-matched (~6 months) weight maintenance period. Insulin sensitivity was assessed by using the hyperinsulinemic-euglycemic clamp procedure (HECP) in conjunction with stable-isotope-labeled glucose tracer infusion and by evaluating muscle AKT phosphorylation. The rate of insulin-stimulated glucose uptake (glucose rate of disappearance [Rd] during the HECP) was the primary outcome. In addition, we evaluated the muscle global transcriptome and a series of factors that can influence insulin action, including: (1) the concentrations of amino acids and their
metabolites (C3[proprionyl]- and C5[isovaleryl]- acylcarnitine) in plasma and the phosphorylation of intramyocellular amino acid targets (mammalian target of rapamycin [mTOR] and its downstream effector, 4E-BP1, and upstream regulator, AMPK) (Newgard et al., 2009; Schooneman et al., 2013; Krebs et al., 2007; Tsai et al., 2015; Tremblay et al., 2005; Saha et al., 2011); (2) plasma free fatty acid (FFA) concentration (Boden and Chen, 1995; Roden et al., 1996), palmitate rate of appearance (Ra) in plasma as an index of adipose tissue lipolytic activity (Mittendorfer et al., 2003a), and the expression of selected genes involved in lipogenesis, and fatty acid oxidation and mitochondrial function in muscle; (3) the gene expression of key enzymes involved in oxidative stress defense in muscle; (4) plasma fibroblast growth factor 21 (FGF21) (Camporez et al., 2013; Mashill et al., 2011; Xu et al., 2009; Markan et al., 2014; Laeger et al., 2014); and (5) the plasma concentration and muscle gene expression of selected inflammatory markers (Pedersen, 2007; Kirk and Klein, 2009).

RESULTS

Baseline Subject Characteristics, Dietary Compliance, and Duration of the Intervention

Baseline characteristics of the study subjects in the WM, WL, and WL-HP groups were not different from each other (Table 1).

Table 1. Subject Characteristics at Screening, Energy and Macronutrient Intake during the Dietary Intervention and Diet-Induced Change in Urinary Urea Nitrogen Excretion Rate

<table>
<thead>
<tr>
<th>Subject Characteristics</th>
<th>WM</th>
<th>WL</th>
<th>WL-HP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60 ± 1</td>
<td>58 ± 1</td>
<td>58 ± 1</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>36 ± 2</td>
<td>35 ± 1</td>
<td>36 ± 1</td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>98 ± 7</td>
<td>95 ± 2</td>
<td>93 ± 2</td>
</tr>
<tr>
<td>Fat-free mass (kg)</td>
<td>51 ± 2</td>
<td>49 ± 1</td>
<td>46 ± 1</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>49 ± 2</td>
<td>48 ± 1</td>
<td>50 ± 1</td>
</tr>
<tr>
<td>Intrahepatic triglyceride content (%)</td>
<td>10.2 ± 3.4</td>
<td>6.6 ± 1.2</td>
<td>8.3 ± 2.8</td>
</tr>
<tr>
<td>Intra-abdominal adipose tissue volume (cm³)</td>
<td>1,596 ± 279</td>
<td>1,404 ± 138</td>
<td>1,341 ± 205</td>
</tr>
</tbody>
</table>

Plasma Concentrations

| Glucose (mg/dL)³ | 95 ± 5 | 96 ± 2 | 94 ± 3 |
| Glucose, 2 hr post-OGTT (mg/dL) | 143 ± 16 | 124 ± 8 | 134 ± 8 |
| Triglycerides (mg/dL)³ | 148 ± 19 | 136 ± 25 | 95 ± 12 |
| Total cholesterol (mg/dL)³ | 215 ± 20 | 215 ± 14 | 203 ± 10 |
| HDL-cholesterol (mg/dL)³ | 56 ± 5 | 60 ± 6 | 59 ± 2 |
| LDL-cholesterol (mg/dL)³ | 129 ± 19 | 128 ± 11 | 124 ± 9 |

Energy, Carbohydrate, and Fat Intake

| Energy (kcal/day) | 1,743 ± 146 | 1,345 ± 57 | 1,389 ± 72 |
| Carbohydrates (% total energy) | 47 ± 1 | 49 ± 2 | 43 ± 1b,c |
| Carbohydrates (% non-protein energy intake) | 58 ± 2 | 63 ± 2 | 63 ± 2 |
| Fat (% total energy) | 34 ± 1 | 29 ± 2 | 26 ± 1b |
| Fat (% non-protein energy intake) | 42 ± 2 | 37 ± 2 | 37 ± 2 |

Protein Intake

| Contribution to total energy (%) | 19 ± 1 | 22 ± 1 | 31 ± 1b,c |
| Grams/day | 81 ± 8 | 73 ± 4 | 105 ± 3b,c |
| Grams/kilogram of body weight/day | 0.79 ± 0.05 | 0.85 ± 0.04 | 1.25 ± 0.03b,c |
| Grams/kilogram of ideal body weightd/day | 1.18 ± 0.11 | 1.09 ± 0.06 | 1.64 ± 0.07b,c |

Urinary Urea Nitrogen Excretion Rate (g/day)

| Before the diet intervention | 10 ± 2 | 11 ± 1 | 10 ± 1 |
| After the diet intervention | 8 ± 1 | 10 ± 1 | 15 ± 2b,c |

Data are expressed as mean ± SEM. WM, weight maintenance (n = 7); WL, weight loss (n = 10); WL-HP, weight-loss high-protein (n = 10); OGTT, oral glucose tolerance test; HDL, high-density lipoprotein; LDL, low-density lipoprotein. See also Figure S4.

³Values were obtained after an overnight fast.

bValue significantly different from corresponding value in the WM group (p < 0.05).

cValue significantly different from corresponding value in the WL group (p < 0.05).

dIdeal body weight is the weight corresponding to a BMI of 24.9 kg/m² (Institute of Medicine, 2005).
the prescribed amounts of 0.8 g per kg body weight per day in the WL group and 1.2 g per kg body weight per day in the WL-HP group; urinary nitrogen excretion rate was ~50% greater (p < 0.01) in the WL-HP group than in the WL group (Table 1). The contribution of carbohydrates (or CHO) and fat to total energy intake was only minimally different (<6%) in the two weight loss groups, and the contribution of carbohydrates and fat to non-protein energy intake was the same (Table 1).

Changes in Body Weight and Composition

Body weight and body composition in the WM group did not change during the intervention. Both the WL and WL-HP groups lost ~10% of their initial body weight, but the contribution of fat-free mass (FFM) to total weight loss was ~45% less in the WL-HP group than in the WL group (p = 0.03) (Figure 1). However, the absolute loss of FFM was small, so that only ~700 g of FFM were preserved in the WL-HP compared with the WL group. Intrahepatic triglyceride (IHTG) content and intra-abdominal adipose tissue (IAAT) volume did not change in the WM group but decreased by ~45% (IHTG) and ~20% (IAAT), respectively, in both the WL and WL-HP groups (p < 0.01 versus the WM group; there was no difference between the WL and WL-HP groups) (Figure 1).

Basal insulin concentration was the same before and after the intervention in the WM group and decreased to the same extent (~30%) after weight loss in the WL and WL-HP groups (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) (Table 2). Glucose and insulin concentrations achieved during the HECp after the intervention were not different from those achieved before the intervention in all three groups (Table 2). Basal FFA concentration did not change in the WM group and decreased to the same extent (~15%) after weight loss in the WL and WL-HP groups. During the HECp, FFA concentration decreased by ~90%, both before and after the interventions, in all three groups (Table 2). Basal branched-chain amino acid concentration was ~8% lower (p < 0.05) after weight loss in both the WL and WL-HP groups (no difference between groups), whereas basal total essential (including branched-chain) and non-essential amino acid concentrations were not affected by weight loss in either the WL group or the WL-HP group. During the HECp, the sum of all (total) and non-essential amino acid concentrations decreased to the same extent in all three groups before and after the intervention. In contrast, the HECp-induced decreases in branched-chain and total essential (including branched-chain) amino acid concentrations were ~15% greater (p < 0.05 after than before weight loss in both the WL and WL-HP groups (Table 2; Figure S1). Plasma C3 and C5 acylcarnitine concentrations did not change in the WL and WL-HP groups (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) but did not change in the WM group (Table 2).
**Table 2. Plasma Hormone and Metabolite Concentrations and Glucose Kinetics Before and After the Dietary Intervention**

<table>
<thead>
<tr>
<th></th>
<th>WM Before</th>
<th>WM After</th>
<th>WL Before</th>
<th>WL After</th>
<th>WL-HP Before</th>
<th>WL-HP After</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma Hormone and Metabolite Concentrations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>Basal</td>
<td>96.2 ± 4.1</td>
<td>94.7 ± 4.3</td>
<td>96.1 ± 3.1</td>
<td>92.9 ± 1.8</td>
<td>92.2 ± 1.3</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>102.3 ± 1.3</td>
<td>102.4 ± 0.9</td>
<td>101.2 ± 1.0</td>
<td>102.5 ± 1.0</td>
<td>100.5 ± 0.9</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>Basal</td>
<td>8.2 ± 1.5</td>
<td>7.0 ± 1.5</td>
<td>5.9 ± 1.1</td>
<td>3.5 ± 0.5</td>
<td>7.7 ± 1.3</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>56.6 ± 6.7</td>
<td>57.0 ± 2.2</td>
<td>53.3 ± 5.3</td>
<td>55.2 ± 5.2</td>
<td>66.3 ± 5.1</td>
</tr>
<tr>
<td>Free Fatty Acids (mM)</td>
<td>Basal</td>
<td>0.71 ± 0.06</td>
<td>0.70 ± 0.04</td>
<td>0.64 ± 0.04</td>
<td>0.54 ± 0.04</td>
<td>0.71 ± 0.06</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>0.10 ± 0.02</td>
<td>0.07 ± 0.01</td>
<td>0.06 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.05 ± 0.01</td>
</tr>
<tr>
<td>Branched-Chain Amino Acids (µM)</td>
<td>Basal</td>
<td>377 ± 19</td>
<td>385 ± 18</td>
<td>375 ± 8</td>
<td>339 ± 15</td>
<td>386 ± 13</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>237 ± 29</td>
<td>235 ± 25</td>
<td>209 ± 14</td>
<td>159 ± 12</td>
<td>216 ± 13</td>
</tr>
<tr>
<td>Essential Amino Acids (µM)</td>
<td>Basal</td>
<td>907 ± 75</td>
<td>942 ± 75</td>
<td>845 ± 25</td>
<td>818 ± 44</td>
<td>830 ± 31</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>661 ± 87</td>
<td>664 ± 77</td>
<td>558 ± 45</td>
<td>468 ± 52</td>
<td>580 ± 41</td>
</tr>
<tr>
<td>Non-essential Amino Acids (µM)</td>
<td>Basal</td>
<td>1,006 ± 90</td>
<td>998 ± 98</td>
<td>921 ± 48</td>
<td>881 ± 53</td>
<td>954 ± 36</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>846 ± 91</td>
<td>799 ± 85</td>
<td>709 ± 49</td>
<td>616 ± 55</td>
<td>770 ± 43</td>
</tr>
<tr>
<td><strong>Total Amino Acids (µM)</strong></td>
<td>Basal</td>
<td>1,913 ± 164</td>
<td>1,940 ± 172</td>
<td>1,766 ± 69</td>
<td>1,699 ± 92</td>
<td>1,784 ± 61</td>
</tr>
<tr>
<td></td>
<td>HECP</td>
<td>1,507 ± 174</td>
<td>1,463 ± 158</td>
<td>1,288 ± 86</td>
<td>1,083 ± 104</td>
<td>1,349 ± 80</td>
</tr>
<tr>
<td>Sum of C3 and C5 acylcarnitines (µM)</td>
<td></td>
<td>0.37 ± 0.05</td>
<td>0.37 ± 0.05</td>
<td>0.39 ± 0.03</td>
<td>0.32 ± 0.02</td>
<td>0.36 ± 0.03</td>
</tr>
<tr>
<td>Fibroblast growth factor 21 (pg/mL)</td>
<td>219 ± 46</td>
<td>247 ± 52</td>
<td>177 ± 36</td>
<td>148 ± 24</td>
<td>168 ± 25</td>
<td>116 ± 13</td>
</tr>
<tr>
<td><strong>Glucose Kinetics</strong></td>
<td>Basal</td>
<td>761 ± 15</td>
<td>780 ± 30</td>
<td>789 ± 36</td>
<td>736 ± 25</td>
<td>784 ± 31</td>
</tr>
<tr>
<td></td>
<td>GIR</td>
<td>15.7 ± 0.6</td>
<td>16.0 ± 0.6</td>
<td>16.3 ± 0.7</td>
<td>15.8 ± 0.6</td>
<td>17.2 ± 0.7</td>
</tr>
<tr>
<td>Glucose Ra (µmol/min)</td>
<td>Basal</td>
<td>2,619 ± 554</td>
<td>2,601 ± 429</td>
<td>2,512 ± 197</td>
<td>2,986 ± 164</td>
<td>2,893 ± 337</td>
</tr>
<tr>
<td></td>
<td>GIR</td>
<td>55.7 ± 13.2</td>
<td>55.0 ± 10.6</td>
<td>52.6 ± 4.9</td>
<td>64.6 ± 4.5</td>
<td>63.2 ± 6.9</td>
</tr>
<tr>
<td>Glucose Rd (µmol/min)</td>
<td>Basal</td>
<td>2,741 ± 537</td>
<td>2,681 ± 383</td>
<td>2,649 ± 214</td>
<td>3,108 ± 184</td>
<td>2,976 ± 317</td>
</tr>
<tr>
<td></td>
<td>GIR</td>
<td>58.2 ± 12.9</td>
<td>56.5 ± 9.6</td>
<td>55.5 ± 5.3</td>
<td>67.3 ± 5.0</td>
<td>65.0 ± 6.5</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. WM, weight maintenance (n = 7); WL, weight loss (n = 10); WL-HP, weight-loss high-protein (n = 10); HECP, hyper-insulinemic-euglycemic clamp procedure; Ra, rate of appearance; FFM, fat-free mass; GIR, glucose infusion rate; Rd, rate of disappearance. See also Figure S1.

*Value significantly different from corresponding basal value (p < 0.05).
*Value significantly different from corresponding value in the WM group (p < 0.05).
*Value significantly different from corresponding value in the WL-HP group (p < 0.01).

**Glucose Kinetics**

Basal glucose Ra and glucose Rd during the HECP in the WM group did not change during the intervention (Table 2). Basal glucose Ra decreased by ~6% after weight loss in both the WL and WL-HP groups (p < 0.05 versus the WM group; no difference between the WL and WL-HP groups) (Table 2). Glucose Ra during the HECP was almost completely (by 85% ± 2%) suppressed in all studies, both before and after weight loss (main effect of clamp, p < 0.001; no significant interactions and no significant main effects of either group or time) (Table 2). Glucose Rd during the HECP increased by 25.3% ± 6.5% (p < 0.01) after weight loss in the WL group, whereas glucose Rd during the HECP after weight loss was not different from before weight loss in the WL-HP group (Figure 1).

By chance, baseline mean glucose Rd during the clamp procedure was 12% higher in the WL-HP group than in the WL and WM groups. This difference was largely driven by one person whose baseline glucose Rd was 5,528 µmol/min (nearly double...
the mean value). The average value in the remaining nine subjects was 2,693 ± 158 μmol/min and nearly identical to the average glucose Rd values in the other two groups (2,741 ± 537 and 2,649 ± 214 μmol/min in the WM and WL groups, respectively). Excluding this subject from the statistical analysis does not affect the results (i.e., HP intake eliminates the weight-loss-induced improvement in insulin-mediated glucose Rd, regardless of whether this person is or is not included in the analysis).

**Intramyocellular Signaling Elements**

During the HEC, muscle phosphorylated (p-)AKTSer473, p-mTORSer2448, and p-4E-BP1Thr37/46 contents increased by ~50%–150% above basal values in the WM, WL, and WL-HP groups (Figures 2 and S2). The increase in p-AKTSer473 during the HEC was greater after than before weight loss (p < 0.05) in the WL group, but it did not change in the WL-HP and WM groups (Figure 2 and S2). The increases in p-mTORSer2448 and p-4E-BP1Thr37/46 during the HEC after weight loss/maintenance in the WL, WL-HP, and WM groups were not different from the increases observed before the intervention (Figure 2 and S2). Muscle p-AMPKThr172 was not affected by the HECP or between weight loss/maintenance in the WL, WL-HP, and WM groups (Figure 2 and S2).

**Palmitate Kinetics and the Expression of Selected Genes Involved in Lipogenesis, and Fatty Acid Oxidation and Mitochondrial Function in Muscle**

Basal palmitate Ra was not different among the WM, WL, and WL-HP groups at baseline (131 ± 15, 119 ± 8, and 123 ± 9 μmol/min, respectively) and was ~15% lower (p < 0.01) after than before the interventions in all groups (118 ± 12, 100 ± 8, and 108 ± 12 μmol/min, respectively). The expression of most of the analyzed genes involved in lipogenesis (CHREBP, ELOVL6, FADS1, FASN, and SREBF1 but not SCD) and fatty acid oxidation and mitochondrial function (COX4/1, CPT1B, PDK4, PPARGC1A, and UCP2) was not affected by HP in the WL and WL-HP groups (Figure 3). Muscle gene expression of SCD (stearoyl-coenzyme A [CoA] desaturase) and ACADM [acyl-CoA dehydrogenase] was lower after than before weight loss in both the WL and WL-HP groups (Figure 3).

**Inflammatory and Oxidative Stress Defense Markers in Plasma and Muscle**

C-reactive protein and interleukin-6 (IL6) concentrations in plasma (Figure S3) and muscle CD68, IL6, MCP1, and tumor necrosis factor (TNF) gene expression did not change during the interventions (Figure 4). Muscle GSTA4 gene expression decreased in the WL group, and PRDX3 gene expression increased in the HL-HP group; SOD1 gene expression decreased after weight loss in both the WL and WL-HP groups, and CAT gene expression did not change in either the WL group or the WL-HP group (Figure 4).
Global Muscle Gene Expression Profiling by Using the Microarray Technique
Twenty-six gene sets were similarly affected by weight loss in the WL and WL-HP groups, and 34 were differently affected by WL in the WL and WL-HP groups (Tables 3, S1, and S2). Of those, several that were related to cell structure and organization were upregulated in the WL group and not affected, or even downregulated, by weight loss in the WL-HP group. A pathway related to the regulation of signal transduction was upregulated, and an oxidative stress gene set pathway was downregulated in the WL group but not in the WL-HP group.

**DISCUSSION**

Although many studies have evaluated the effect of HP diets on metabolic function, the results from several systematic reviews and meta-analyses indicate that it is not possible to determine the effect of HP intake, per se, on insulin sensitivity because of differences in overall diet composition (food selection and nutrient composition) and amount of weight loss between the HP-intervention and control groups (Rietman et al., 2014; Wycherley et al., 2012; Schwingshackl and Hoffmann, 2013). Therefore, we conducted an RCT to evaluate the effect of dietary protein intake on body composition and insulin sensitivity by providing a protein supplement to subjects during weight loss to minimize the potential confounding influences of differences in overall diet composition on our outcome measures. In addition, participants who were given a standard-protein hypocaloric diet (0.8 g protein/kg per day) and those given a HP hypocaloric diet (1.2 g protein/kg per day) were assessed before and after matched (~10%) weight loss. We found that the WL-HP diet blunted the weight loss-induced decline in FFM by ~45%. Howev-

**Figure 3. Expression of Genes Involved in Lipogenesis, and Fatty Acid Oxidation and Mitochondrial Function in Muscle**

(A–L) Expression of genes involved in lipogenesis (A: carbohydrate response element binding protein [CHREBP]; B: elongation of very long-chain fatty acids protein 6 [ELOVL6]; C: fatty acid desaturase 1 [FADS1]; D: fatty acid synthase [FASN]; E: stearoyl CoA desaturase [SCD]; and F: sterol regulatory element binding transcription factor 1 [SREBF1]) and in fatty acid oxidation and mitochondrial function (G: acyl-coenzyme A dehydrogenase [ACADM]; H: cytochrome C oxidase subunit IV [COX4/1]; I: carnitine palmityl transferase 1 [CPT1B]; J: pyruvate dehydrogenase kinase 4 [PDK4]; K: peroxisome proliferator-activated receptor gamma coactivator 1 alpha [PPARGC1A], and L: uncoupling protein 2 [UCP2]) in muscle before (white bars) and after (black bars) weight loss in subjects consuming the standard weight-loss (WL) diet and weight-loss high-protein (WL-HP) diet. Data (n = 6–9) are expressed relative to the housekeeping gene and presented as mean ± SEM, except for ACADM, FASN1, and SCD, which are expressed as median (quartiles). #Significant main effect of weight loss (p < 0.05). §Significant main effect of group (p < 0.05). See also Table S3.
Muscle insulin sensitivity in the WL-HP group is clinically important because it reflects a failure to improve a major pathophysiological mechanism involved in the development of T2D (Groop, 1999; Petersen and Shulman, 2002) and indicates that more insulin is required in the WL-HP group than in the WL group to dispose of a given amount of glucose. In summary, our data, therefore, demonstrate that the protein content of a weight loss diet can have profound effects on metabolic function and underscore the importance of considering dietary macronutrient composition in conjunction with energy content itself in weight loss therapy for people with obesity.

The mechanism(s) responsible for the adverse effect of HP intake on insulin action are unclear. Failure to improve insulin-stimulated glucose uptake in the WL-HP group compared to the WL group occurred in the absence of any major differences in body weight, body composition, plasma FFA availability, and inflammatory markers in plasma or muscle in the two groups. Data from studies conducted in cultured myotubes, isolated rat skeletal muscles, and transgenic mice have demonstrated that amino acids—particularly the branched-chain amino acid leucine—can impair insulin-mediated glucose uptake by AMPK-mediated mTOR phosphorylation and subsequent negative feedback inhibition of phosphatidylinositol 3-kinase (PI3K)-AKT signaling (Iwanaka et al., 2010; Saha et al., 2011) or possibly downstream signaling to 4E-BP1 (Tsai et al., 2015). In contrast, we recently found that these pathways were not involved in the inhibition of insulin-mediated glucose uptake that occurred with acute protein ingestion in people (Smith et al., 2015). In the present study, we also found that chronic HP intake impaired the weight loss-induced improvement in insulin-mediated glucose uptake in the absence of differences in p-AMPK<sub>Thr172</sub>, p-mTOR<sub>Ser2448</sub>, and p-4E-BP1<sub>Thr37/46</sub> in muscle. Data from several recent studies have implicated other amino acids in the inhibition of insulin-mediated glucose uptake that occurred with acute protein ingestion in people (Smith et al., 2015). In the present study, we also found that chronic HP intake impaired the weight loss-induced improvement in muscle.

Figure 4. Expression of Genes Involved in Inflammatory and Oxidative Stress Defense Pathways in Muscle
(A–H) Expression of genes involved in inflammatory (A: cluster of differentiation 68 [CD68]; C: interleukin-6 [IL6]; E: monocyte chemoattractant protein 1 [MCP1]; and G: tumor necrosis factor [TNF]) and oxidative stress defense (B: catalase [CAT]; D: glutathione S-transferase alpha 4 [GSTA4]; F: peroxiredoxin 3 [PRDX3]; and H: superoxide dismutase 1 [SOD1]) pathways before (white bars) and after (black bars) weight loss in subjects consuming the standard weight-loss diet (WL) and weight-loss high-protein (WL-HP) diet. Data (n = 6–9) are expressed relative to the housekeeping gene and presented as mean ± SEM, except for IL6, MCP1, and TNF, which are expressed as median (quartiles). *Value significantly different from corresponding basal value (p < 0.05). **Value significantly different from all other values (p < 0.05). #Significant main effect of weight loss (p < 0.05). See also Figure S3 and Table S3.
acids (e.g., glycine and tryptophan) and the amino acid metabolites C3- and C5-acylcarnitine in the development of insulin resistance as well (e.g., Schooneman et al., 2013; Hattersley et al., 2014), but we found no differences in the plasma amino acid profile between the WL and WL-HP groups. Weight loss reduced basal plasma branched-chain amino acid concentrations and tended to decrease the plasma concentrations of the amino acid metabolites C3- and C5-acylcarnitine in both the WL and WL-HP groups without a difference between groups; the decline in both branched-chain and total essential (including branched-chain) amino acid concentrations during the HECP was also greater after than before weight loss in both the WL and WL-HP groups without a difference between groups. These findings suggest that the adverse effect of HP intake on insulin action during weight loss was not due to differences in circulating amino acids or their metabolites.

It is also unlikely that the adverse effects of HP intake on insulin action were mediated by FGF21, which has been shown to increase insulin sensitivity in rodent models (Camporez et al., 2013; Mashili et al., 2011; Xu et al., 2009; Markan et al., 2014). Although plasma FGF21 concentration increases after severe protein (Laeger et al., 2014) and calorie restriction (Gálman et al., 2008; Fazeli et al., 2015), we found that moderate weight loss decreased basal FGF21 concentration and had no effect on plasma FGF21 concentration during the HECP in both the WL and WL-HP groups.

An imbalance in cellular redox status is considered a key mechanism for the development of muscle insulin resistance in persons with obesity (Muio and Neufer, 2012; Anderson et al., 2009). Our microarray analysis results suggest that oxidative-stress-related metabolic processes in muscle decreased after weight loss in the WL group, but not the WL-HP group, and weight loss in the WL group, but not the WL-HP group, also decreased the gene expression of GSTA4. GSTA4 is a member of the glutathione S-transferase family, and its expression is a marker of oxidative stress burden (Frohnert et al., 2014; Raza et al., 2002). Weight loss in the WL-HP group, on the other hand, increased the gene expression of PRDX3 in muscle. PRDX3 is a member of the peroxiredoxin family of antioxidants within mitochondria, and experimentally induced oxidative stress in animal models increases PRDX3 tissue expression (Schröder et al., 2008); in people, gene expression of PRDX3 is also increased in conditions that are associated with oxidative stress, such as cancer (Whitaker et al., 2013; Kim et al., 2009). These results suggest that the adverse effect of HP intake on insulin action during weight loss therapy may have been mediated through its effects on oxidative stress because it prevented the WL-induced decrease, and even increased, metabolic pathways involved in oxidative stress response in muscle.

Our microarray analysis also identified a series of gene set pathways related to intracellular and extracellular structure and organization that were upregulated by weight loss in the WL group but not changed, or even decreased, in the WL-HP group. The intracellular cytoskeleton and extracellular matrix of muscle cells are important in regulating muscle insulin action by providing a scaffold that serves as a binding site for signaling molecules and for transporting GLUT4 from intracellular vesicles to the plasma membrane (Liu et al., 2013; Klip et al., 2014; Asrih et al., 2011; Bose et al., 2002; Zaid et al., 2008; Brozinick et al., 2007; Chen et al., 2007). Our data, therefore, suggest that adaptations in pathways related to tissue structural biology are involved in the weight loss-induced improvement in muscle insulin action, which were prevented by HP intake.

### Table 3. Key Gene Set Pathways that Were Differently Affected by WL and WL-HP Diets

<table>
<thead>
<tr>
<th>Gene set name</th>
<th>WL Z-score</th>
<th>P-value</th>
<th>WL-HP Z-score</th>
<th>P-value</th>
<th>Heat map</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extracellular_matrix</td>
<td>6.68</td>
<td>&lt;0.001</td>
<td>-1.55</td>
<td>0.120</td>
<td>+6</td>
</tr>
<tr>
<td>Proteinaceous_extracellular_matrix</td>
<td>6.56</td>
<td>&lt;0.001</td>
<td>-1.68</td>
<td>0.090</td>
<td></td>
</tr>
<tr>
<td>Actin_cytoskeleton</td>
<td>4.61</td>
<td>&lt;0.001</td>
<td>-0.08</td>
<td>0.939</td>
<td></td>
</tr>
<tr>
<td>Actin_filament_based_movement</td>
<td>4.02</td>
<td>&lt;0.001</td>
<td>0.66</td>
<td>0.509</td>
<td></td>
</tr>
<tr>
<td>Cytoskeleton</td>
<td>3.76</td>
<td>&lt;0.001</td>
<td>-0.40</td>
<td>0.690</td>
<td></td>
</tr>
<tr>
<td>Myosin_complex</td>
<td>3.73</td>
<td>&lt;0.001</td>
<td>-0.31</td>
<td>0.753</td>
<td></td>
</tr>
<tr>
<td>Extracellular_matrix_part</td>
<td>3.61</td>
<td>&lt;0.001</td>
<td>-1.29</td>
<td>0.198</td>
<td></td>
</tr>
<tr>
<td>Cytoskeletal_part</td>
<td>3.50</td>
<td>&lt;0.001</td>
<td>-0.45</td>
<td>0.652</td>
<td></td>
</tr>
<tr>
<td>Endoplasmic_reticulum</td>
<td>1.71</td>
<td>0.087</td>
<td>-3.60</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Intracellular_organellle_part</td>
<td>-0.44</td>
<td>0.967</td>
<td>-4.01</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Organellle_part</td>
<td>-0.04</td>
<td>0.964</td>
<td>-3.40</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Organellle_membrane</td>
<td>-1.53</td>
<td>0.126</td>
<td>-4.14</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Regulation_of_signal_transduction</td>
<td>3.43</td>
<td>&lt;0.001</td>
<td>-1.21</td>
<td>0.226</td>
<td></td>
</tr>
<tr>
<td>Oxidative stress</td>
<td>-4.10</td>
<td>&lt;0.001</td>
<td>-1.32</td>
<td>0.187</td>
<td></td>
</tr>
</tbody>
</table>

WL, weight-loss (n = 6); WL-HP, weight-loss high-protein (n = 9). See also Tables S1 and S2.
Although we found that HP intake during weight loss attenuates the beneficial effect of moderate weight loss on muscle insulin action, this does not mean that an HP weight loss diet necessarily results in a diminished improvement in plasma glucose homeostasis. 24-hr glycemic control is determined by both postabsorptive and postprandial plasma glucose concentrations, which are determined by glucose Ra into plasma (from endogenous and exogenous/dietary sources) and glucose Rd from plasma. Both endogenous glucose Ra and glucose Rd are regulated by insulin, and the metabolic response to insulin across the range of physiological concentrations (basal, postabsorptive to peak postprandial) differs among organs. Endogenous (mostly hepatic) glucose production is much more sensitive to insulin than is muscle glucose uptake and is nearly completely suppressed at plasma insulin concentrations that only minimally stimulate muscle glucose uptake (Conte et al., 2012). The decline in basal plasma insulin concentration after weight loss without a change in plasma glucose concentration and a slight reduction in basal glucose Ra, suggests that weight loss in both the WL and WL-HP groups may have improved hepatic insulin sensitivity. On the other hand, our use of the HECP, in conjunction with stable isotopically labeled glucose tracer infusion and an insulin infusion rate that results in systemic plasma insulin concentrations within the postprandial range, allowed us to measure muscle insulin sensitivity, and our data demonstrate that HP intake prevented the WL-induced improvement in muscle insulin sensitivity.

Diabetic protein is a potent insulin secretagogue (Floyd et al., 1966; Ang et al., 2012; Manders et al., 2014), which may overcome the adverse effect of protein on insulin sensitivity by increasing the secretion of insulin. In addition, protein causes greater satiation and has a greater thermogenic effect of feeding than carbohydrate and fat, which can lead to greater weight loss with an HP than a standard protein diet (Wycherley et al., 2012; Leidy et al., 2015). Therefore, the adverse effect of dietary protein on muscle insulin action could be offset by its effect on hepatic insulin sensitivity, insulin secretion, and energy balance.

In summary, the results from our study demonstrate that HP intake during weight loss helps preserve FFM but eliminates the beneficial effect of weight loss on skeletal muscle insulin action. The mechanisms responsible for the adverse effect of HP intake on muscle insulin action are not clear. Our data suggest that HP intake causes alterations in muscle cell structure and organization and oxidative stress, which are involved in preventing the therapeutic effect of weight loss on muscle insulin action, whereas changes in circulating amino acids, including branched-chain amino acids and their metabolites, plasma FGF21 concentration, muscle mTOR signaling, and inflammatory pathways in muscle, are not involved.

**EXPERIMENTAL PROCEDURES**

**Subjects and Study Design**

Thirty-four sedentary (< 1.5 hr exercise per week) and weight-stable (< 2 kg change for at least 6 months), 50- to 65-year-old postmenopausal women with obesity were included in this study (ClinicalTrials.gov number NCT01538838), which was approved by the Human Research Protection Office at the Washington University School of Medicine. Written informed consent was obtained from all subjects before their participation in the study. We specifically chose to study only postmenopausal women with obesity because we wanted to study a population for whom weight loss with increased protein intake is often recommended to reduce the risk of sarcopenia (Houston et al., 2009; Wolfe et al., 2008).

The flow of study subjects is shown in Figure S4. All subjects were evaluated by a history and physical examination, a resting 12-lead electrocardiogram, standard blood tests, and an oral glucose tolerance test. None of the subjects had evidence of chronic illness or significant organ dysfunction (e.g., diabetes mellitus, liver cirrhosis) or were taking medications (including hormone replacement therapy) that could affect insulin or glucose metabolism, and none consumed tobacco products, reported regular consumption of >115 g of alcohol per week, or scored >2 points (out of a possible 22) on the Michigan Alcohol Screening Test.

After subjects completed body composition analyses and an HECP, they were randomized to one of three intervention groups: (1) a WM group; (2) a WL group, who consumed an energy-reduced diet containing 0.8 g protein/kg body weight per day; and (3) a WL-HP group, who consumed an energy-reduced diet containing 1.2 g protein/kg body weight per day. All outcomes were evaluated before and after subjects randomized to the weight loss groups lost 8%–10% of their body weight or a time-matched weight maintenance period for those randomized to the WM group. Twenty-seven subjects completed the study and were included in the analysis; their characteristics are shown in Table 1. The baseline characteristics of the seven subjects who dropped out of the study (Figure S4) were not different from those who completed the study (data not shown).

**Outcomes Assessment**

**Body Composition**

Fat mass and FFM were determined by using dual-energy X-ray absorptiometry (DXA; Lunar iDXA, GE Healthcare Lunar), and IAAT volume and IHTG were determined by using MRI/spectroscopy (1.5-T superconducting magnet; Siemens), as previously described (Frimel et al., 2007; Magkos et al., 2007).

**Insulin Action—HECP**

Subjects were instructed to refrain from vigorous physical activities for 3 days before being admitted to the Clinical Research Unit, where they consumed a standard 800 kcal dinner (50% carbohydrate [or CHO], 30% fat, 20% protein) between 1800 hr and 1900 hr. In addition, all subjects consumed a 100-kcal liquid meal supplement (Ensure, Abbott Laboratories, containing 15% of energy as protein, 55% as carbohydrate, and 30% as fat) at baseline (before the dietary intervention); after the intervention, subjects in the WM and WL groups consumed the same liquid meal supplement, and subjects in the WL-HP group consumed a 100-kcal whey protein solution (Unjury, ProSynthesis Laboratories) containing 21 g protein. Subjects then fasted, except for water, until the next morning. At 0600 hr, catheters were inserted into an arm vein for the infusion of stable-isotope-labeled tracers, and later insulin and dextrose, and into a radial artery for blood sampling. At ~0645 hr, a constant infusion of [U-13C16]palmitate (infusion rate: 6 nmol x kg body weight⁻¹ min⁻¹) and a primed, constant infusion of [6,6-²H₂]glucose (priming dose: 22 μmol x kg body weight⁻¹; infusion rate: 0.22 μmol x kg body weight⁻¹ x min⁻¹), both purchased from Cambridge Isotope Laboratories, were started and maintained for 4 hr. Upon completion of the basal period, an HECP was initiated with two 5-min priming doses (first 200 μM x m⁻² body surface area [BSA] x min⁻¹, then 100 μM x m⁻² BSA x min⁻¹) of human insulin (Novolin R, Novo Nordisk), followed by constant infusion of insulin at a rate of 50 μM x m⁻² BSA x min⁻¹. Euglycemia (at a blood glucose concentration of ~100 mg/dl) was maintained by variable rate infusion of 20% dextrose (Baxter) enriched to 2.5% with [6,6-²H₂]glucose. Blood samples to determine plasma metabolite and hormone concentrations as well as glucose and palmitate kinetics were obtained immediately before starting the tracer infusions and every 6–7 min during the last 20 min of the basal period and the HECP; additional blood samples were obtained every 10 min during the HECP to monitor blood glucose concentration. Muscle tissue from the quadriceps femoris was obtained by using a Tilley-Henkel forceps 60 min after starting the glucose tracer infusion (basal period) and 180 min after starting the insulin infusion. The basal and HECP biopsies were taken through separate incisions (~5 cm apart) from the right leg before and after the intervention.
**Blood and Tissue Sample Processing and Analyses**

Plasma glucose concentration was determined by using an automated glucose analyzer (Yellow Spring Instruments). ELISAs were used to determine insulin (EMD Millipore), C-reactive protein, IL6, and FGF21 (all from R&D Systems) concentrations. Plasma amino acid concentrations were determined by using the E2faast physiological (free) amino acid kit ( Phenomenex) and gas chromatography/mass spectrometry (GC-MS; Hewlett-Packard MS 5973 system with capillary column) analysis per manufacturer instructions. Total plasma FFA concentration was quantified by using an enzymatic colorimetric assay (Wako Diagnostics). Plasma glucose and palmitate tracer-to-tracer ratios (TTRs) were determined by using GC-MS as previously described (Smith et al., 2015; Middendorfer et al., 2003b). C3- and C5-acylcarnitine concentrations in plasma were quantified by using liquid chromatography–tandem mass spectrometry (LC-MS/MS; Applied Biosystems Sciex 4000QTRAP with Eclipse C18 column) after adding known amounts of propionyl-L-carnitine (N-trimethyl-d3) and isovaleryl-L-carnitine (N,N,N-trimethyl-d3) (both purchased from Cambridge Isotope Laboratories) as internal standards and their conversion to methyl esters as described (with minor modifications) by Forni et al. (2010).

Western blot analysis was used to quantify the contents of p-AKTSer473, p-mTORSer2448, p-4E-BPThr37/46, and p-AMPKThr172 in muscle. Frozen muscle tissue was homogenized in ice-cold cell lysis buffer (Cell Signaling Technology), and proteins were extracted as previously described (Yoshino et al., 2012). Thirty micrograms of protein from each sample were loaded onto polyacrylamide gels (Bio-Rad Laboratories), separated by SDS-PAGE, and transferred to Immob-Blot polyvinylidene difluoride membranes (Bio-Rad). The blotted membranes were incubated with the following primary antibodies (all from Cell Signaling Technology, except for TUBULIN, which was purchased from Sigma-Aldrich): rabbit monoclonal anti-phospho-AKT (Ser473) and anti-total-AKT; rabbit polyclonal anti-phospho-mTOR (Ser2448) and anti-total-mTOR; rabbit polyclonal anti-phospho-4E-BP1 (Thr37/46) and anti-total-4E-BP1; rabbit monoclonal anti-phospho-AMPKα (Thr172); rabbit polyclonal anti-total-AMPKα; and mouse monoclonal anti-α-TUBULIN. All except for TUBULIN blots were incubated with a horseradish-peroxidase-conjugated secondary antibody from Cell Signaling Technology; the α-TUBULIN blot was incubated with a horseradish-peroxidase-conjugated secondary antibody from Santa Cruz Biotechnology. Blots were developed by using the Amersham ECL Select Western Blotting Detection Reagent (GE Healthcare Life Sciences). The contents of p-AKTSer473/p-mTORSer2448, p-4E-BPThr37/46, and p-AMPKThr172 were expressed relative to a single sample loading control and relative to total AKT, mTOR, 4E-BP1, AMPK, or TUBULIN (p-AKTSer473 only). The results were the same, regardless of the control protein used.

The expression of genes involved in inflammatory (CD68, IL6, MCP1, and TNF), oxidative stress defense (CAT, GSTA4, SOD1, and PRDX3), lipogenic (CHREBP, ELOVL6, FADS1, FASN, SCD, and SREBP1), and fatty acid oxidation and mitochondrial function (ACADM, COX4I1, CPT1B, PDK4, PPARGC1A, and UCP2) pathways in muscle were analyzed by using the real-time PCR technique after total RNA was isolated from frozen muscle samples by using TRIzol reagent (Invitrogen), quantified spectrophotometrically (NanoDrop 1000, Thermo Scientific), and reverse transcribed (High-Capacity cDNA Reverse Transcription Kit, Invitrogen). Gene expression was determined by using an ABI 7500 RT-PCR system (Invitrogen) and SYBR Green Master Mix (Invitrogen) as previously described (Smith et al., 2014; Yoshino et al., 2014). The expression of each gene was determined by normalizing the cycle threshold value of each sample to the housekeeping control gene, ribosomal protein RPLP0. Primer details are listed in Table S3.

Microarray analyses were performed with the GeneChip Human Gene 1.0 ST Array (Affymetrix), and pathways that were significantly altered by the dietary interventions were identified by using the R statistical software package and parametric analysis of gene set enrichment (PAGE), as previously described (Fabbri et al., 2015; Yoshino et al., 2011; Kim and Volsky, 2005). Gene sets used in PAGE were obtained from http://www.broadinstitute.org/gsea/msigdb/msigdb_index.html (CS: GO [Gene Ontology] gene sets collection). Z scores and p values were calculated for each gene set. Microarray results were deposited in the NCBI GEO database (accession number GEO: GSE73525).

**Glucose and Palmitate Kinetics Calculations**

The Ra of unlabeled glucose in plasma, which represents the endogenous glucose production rate during basal conditions, was calculated by dividing the glucose tracer infusion rate by the average plasma glucose TTR during the last 20 min of the basal period and the last 20 min of the HECP. During the HECP, total glucose Ra, which equals glucose Rd from plasma, was calculated as the sum of endogenous glucose production plus the rate of infused glucose (dextrose plus tracer). Palmitate Ra in plasma was calculated by dividing the tracer infusion rate by the average plasma palmitate TTR during the last 20 min of the basal period.

**Diet Intervention**

Subjects attended weekly sessions led by an experienced weight management dietitian to ensure compliance with the diet prescription, monitor body weight, and counsel subjects throughout the dietary intervention. The energy content of the initial packed meals given to the weight loss groups was targeted to provide 30% fewer calories than each person’s estimated total daily energy expenditure, based on their resting metabolic rate (RMR) multiplied by an activity factor of 1.4 (Black et al., 1996); subsequent meals and dietary intake were adjusted weekly as needed to achieve a 0.5%–1% weight loss per week until 8%–10% was achieved. Once the targeted weight loss goal was achieved, dietary energy intake was modified to maintain a stable body weight for 3–4 weeks before the testing procedures performed at baseline were repeated. Protein intake and macronutrient distribution of the diet were kept constant in accordance with the initial diet prescription throughout the intervention period. In the WM group, each subject’s energy intake was adjusted as needed to maintain body weight within 2% of the initial body weight. Target protein intake for the WL group was 0.8 g protein/kg body weight per day and 1.2 g protein/kg body weight per day for subjects in the WL-HP group.

All subjects were provided with a base diet of frozen entrees (eLiving meals, Morrison Healthcare; Lean Cuisine, Nestlé USA; Revv Kitchen) for lunch and dinner. Breakfast, subjects consumed two energy bars (NuGo Nutrition) per day. Subjects in the WL-HP diet group also consumed two servings of a whey protein isolate (Unjury, ProSynthesis Laboratories) per day, whereas subjects in the WL group consumed snacks that provided mostly carbohydrates and fat (in proportion to their contribution to total non-protein dietary energy content of the base diet; i.e., ~63 and 37%, respectively) instead. Additional calories needed to meet each subject’s total energy and macronutrient requirements were consumed as fruits, vegetables, dairy products, and starches. Dietary compliance was monitored by having subjects record their dietary intake every day by using the https://www.myfitnesspal.com computer app; the study dietitian reviewed diet records weekly. In addition, 24-hr urinary urea nitrogen excretion was evaluated before and during the final week of the dietary intervention.

**Statistical Analyses**

All datasets were tested for normality by using the Kolmogorov-Smirnov test. One-way ANOVA was used to compare basic characteristics of the study subjects, their macronutrient intake, and baseline metabolic characteristics in each of the three groups. Analysis of covariance with the baseline value as covariate was used to evaluate the effect of the dietary interventions on study outcomes that were measured during basal or HECP conditions only. ANOVA with group (WL versus WL-HP, condition (basal versus clamp), and time (pre- versus post-intervention) as factors, as appropriate, was used to evaluate the effects of dietary interventions on outcomes that were measured during basal conditions and during the HECP; and significant interactions were followed by Tukey’s post hoc procedure to locate significant mean differences. A p value ≤ 0.05 was considered statistically significant for all data, except our microarray data. Treatment-induced changes in gene set pathway expression identified by microarray analysis were considered significant if p ≤ 0.001, and a difference in Z scores > 1.96 was considered a significant difference between the WL and WL-HP groups. Data are presented as mean ± SEM, unless indicated otherwise.

**ACCESSION NUMBERS**

The accession number for the microarray data reported in this paper is NCBI GEO: GSE73525.
SUPPLEMENTAL INFORMATION

Supplemental Information includes four figures and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.09.047.

AUTHOR CONTRIBUTIONS


ACKNOWLEDGMENTS

S.K. is a shareholder of Aspire Biotics and has served on scientific advisory boards for Takeda Pharmaceuticals and Novo Nordisk. The authors thank Emily Lake, Janet Winkelmann, Lynda Bowers, and Kathryn Gratza for help with subject recruitment, scheduling, and testing; Kelly Stromsdorfer, Freida Custodio, and Jennifer Shew for their technical assistance; the staff of the Clinical Research Unit for their help in performing the studies; and the study subjects for their participation.

This publication was made possible by NIH grants DK34483, DK56341 (Nutrition and Obesity Research Center), DK20579 (Diabetes Research Center), GM103422 (Biomedical Mass Spectrometry Resource), and UL1TR000448 (Clinical Translational Science Award), including KL2 sub-award TR000450, a Central Society for Clinical and Translational Research Early Career Development Award, and a grant from the Longer Life Foundation.

Received: December 22, 2015
Revised: August 16, 2016
Accepted: September 15, 2016
Published: October 11, 2016

REFERENCES


Cell Reports 17, 849–861, October 11, 2016 859


Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52, 758–763.

Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52, 758–763.

Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52, 758–763.

Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52, 758–763.

Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52, 758–763.

Mittendorfer, B., Liem, O., Patterson, B.W., Miles, J.M., and Klein, S. (2003a). What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes 52, 758–763.